TG Therapeutics, Inc. $TGTX Stake Raised by Trust Co of the South

Trust Co of the South grew its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 229.6% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 25,298 shares of the biopharmaceutical company’s stock after acquiring an additional 17,623 shares during the period. Trust Co of the South’s holdings in TG Therapeutics were worth $1,411,000 as of its most recent filing with the SEC.

Several other large investors have also recently made changes to their positions in TGTX. BlackRock Inc. purchased a new position in shares of TG Therapeutics during the 2nd quarter worth approximately $1,211,429,000. Bank of America Corp DE acquired a new stake in TG Therapeutics in the 2nd quarter valued at approximately $71,960,000. Pictet Asset Management Holding SA increased its holdings in TG Therapeutics by 19.6% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,747,373 shares of the biopharmaceutical company’s stock valued at $58,048,000 after purchasing an additional 286,325 shares during the last quarter. Bank of New York Mellon Corp acquired a new stake in TG Therapeutics in the 2nd quarter valued at approximately $49,472,000. Finally, Dimensional Fund Advisors LP raised its position in TG Therapeutics by 129.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,084,855 shares of the biopharmaceutical company’s stock valued at $36,029,000 after purchasing an additional 612,068 shares during the period. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the sale, the director directly owned 168,640 shares in the company, valued at $9,268,454.40. This represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 8.87% of the stock is currently owned by company insiders.

TG Therapeutics Trading Down 0.1%

NASDAQ TGTX opened at $53.16 on Friday. The firm has a 50 day simple moving average of $54.62 and a 200-day simple moving average of $48.80. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. TG Therapeutics, Inc. has a one year low of $26.76 and a one year high of $59.30. The firm has a market cap of $8.14 billion, a price-to-earnings ratio of 19.40, a PEG ratio of 2.25 and a beta of 1.80.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). TG Therapeutics had a net margin of 55.22% and a return on equity of 73.49%. The business had revenue of $240.34 million during the quarter, compared to analyst estimates of $229.77 million. During the same quarter last year, the firm posted $0.17 EPS. The company’s revenue for the quarter was up 70.2% on a year-over-year basis. Equities research analysts anticipate that TG Therapeutics, Inc. will post 0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 6th. JPMorgan Chase & Co. lifted their price objective on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Bank of America lifted their price objective on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research note on Tuesday, July 7th. HC Wainwright reiterated a “buy” rating and issued a $78.00 price objective on shares of TG Therapeutics in a report on Tuesday, September 1st. Finally, B. Riley Financial increased their target price on TG Therapeutics from $55.00 to $86.00 and gave the stock a “buy” rating in a research note on Monday, July 27th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $63.00.

About TG Therapeutics

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company’s research and development programs are centered on therapies that target B cells and the immune system.

TG Therapeutics’ primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults.